News | November 17, 2008

Damage Inflicted During Cardiac Attacks More Widespread than Previously Thought

November 18, 2008 - Cholesterol crystals released in the bloodstream during a cardiac attack or stroke can damage artery linings much further away from the site of the attack, leaving survivors at greater risk than previously thought, say researchers from Michigan State University.

George Abela, M.D., in Michigan State University's College of Human Medicine and chief of the department of medicine's cardiology section, is leading innovative research into the role that the crystallization and expansion of cholesterol play in heart attacks, strokes and other cardiovascular events in humans. He presented his latest research last week at the American Heart Association's 2008 Scientific Sessions meeting in New Orleans.
In recent medical trials, Abela and his team of researchers tested carotid arteries in a laboratory by injecting cholesterol crystals into them.

"Cholesterol has been shown to expand when crystallizing and then be released into the circulation following a cardiac event," Dr. Abela said. "We found that the flow of sharp-ended crystals in arteries damage the lining of arteries and decrease the ability of arteries to dilate properly at intervals far away from the site of the attack."

Abela compared the process to a tree, with the trunk as the site of the cardiac event and the branches representing arteries where damage is afflicted far away from the trunk.

"These findings have important clinical implications," Abela said. "We found the original injury was being transmitted downstream. We may need to expand the testing that we have patients undergo to make sure more damage is not being done during a cardiac attack or stroke."

For more information: www.msu.edu


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now